logo
Share SHARE
FONT-SIZE Plus   Neg

Enzo Biochem Presents New AmpiProbe Nucleic Acid Amplification Platform Details

Enzo Biochem Inc. (ENZ) announced that it has made its first peer-reviewed presentation of its novel AmpiProbe platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at the annual meeting in London of the European Society of Clinical Microbiology and Infectious Diseases or ESCMID.

The company said its presentation, titled "Quantitative Detection of HCV RNA in Human Plasma-Serum using the Enzo AmpiProbe HCV RNA Assay," detailed the specifications and performance characteristics of the first diagnostic product developed utilizing the AmpiProbe platform.

Enzo's AmpiProbe Hepatitis C virus RNA assay was tested over hundreds of clinical samples and found to be reproducible, accurate and precise, the presentation indicated. In addition, the AmpiProbe HCV RNA assay was found, as compared to similar diagnostics products, to achieve a greater enhanced sensitivity that allows for a more convenient and efficient workflow requiring significantly less starting material.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Facebook's Chief Operating Officer Sheryl Sandberg said the company would be a founding partner of Station F start-up garage in Paris. There will be more than 3000 desks for tech companies at the start-up garage. In its first ever start-up project, Facebook plans to have 80 desks and would initiate the activities by April. Book retailer Barnes & Noble has pulled off from shelves its Nook tablet due to a faulty charger, after launching the cheap 7-inch tablet in November to take on Amazon's popular Fire tablets. Nook tablet has been removed from brick and mortar stores as well from online. Barnes & Noble has not issued... Morgan Stanley (MS) reported fourth-quarter net income applicable to company of $1.7 billion, or $0.81 per share compared with income of $908 million, or $0.39 per share, for the same period a year ago. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share...
comments powered by Disqus
Follow RTT